Experimental Hematology
Volume 36, Issue 1 , Pages 28-36 , January 2008

Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors

  • Pierre Champelovier

      Affiliations

    • Laboratoire de Dynamique Cellulaire de l'EPHE, Université Joseph Fourier, Grenoble, France
    • Corresponding Author InformationOffprint requests to: Pierre Champelovier, M.D., Laboratoire de Cytologie, Centre Hospitalier Universitaire de Grenoble, BP 217X, 38043 Grenoble Cedex 09, France
    • ,
  • Michèle El Atifi

      Affiliations

    • Equipe Transcriptome, Laboratoire de Neurosciences Précliniques, Université Joseph Fourier, Grenoble, France
    • ,
  • Virginie Pautre

      Affiliations

    • Equipe Transcriptome, Laboratoire de Neurosciences Précliniques, Université Joseph Fourier, Grenoble, France
    • ,
  • Béatrice Rostaing

      Affiliations

    • Equipe Transcriptome, Laboratoire de Neurosciences Précliniques, Université Joseph Fourier, Grenoble, France
    • ,
  • François Berger

      Affiliations

    • Equipe Transcriptome, Laboratoire de Neurosciences Précliniques, Université Joseph Fourier, Grenoble, France
    • ,
  • Daniel Seigneurin

      Affiliations

    • Laboratoire de Dynamique Cellulaire de l'EPHE, Université Joseph Fourier, Grenoble, France

Received 29 March 2007 ,Revised 13 July 2007 ,Accepted 20 August 2007.

References 

  1. Yang S-H, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene. 2003;320:3–21
  2. Dangi S, Cha H, Shapiro P. Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cell Signal. 2003;15:667–675
  3. Liu X, Yan S, Zhou T, Terada Y, Erikson RL. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene. 2004;23:763–776
  4. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912
  5. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–1331
  6. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanisms of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105
  7. Champelovier P, Seigneurin D, Leroux D, Micouin C, Kolodie L. Establishment and characterisation of a granulocytic subclone (UM384) from the monoblastic cell line U937. Exp Hematol. 1989;17:779–784
  8. Champelovier P, Pautre V, El Atifi M, et al. Resistance to phorbol ester-induced differentiation in human myeloid leukemia cells: a hypothetic role for the mRNA stabilization process. Leukemia Res. 2006;30:1407–1416
  9. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179–205
  10. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A. 1978;75:2458–2462
  11. Georgakis GV, Li Y, Rasssdakis GZ, et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006;132:503–511
  12. Moon D-O, Park C, Heo M-S, et al. PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway. Int Immunopharmacol. 2007;7:36–45
  13. Usui T, Yoshida M, Abe K, Osada H, Isono K, Beppu T. Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J Cell Biol. 1991;115:1275–1282
  14. Chang B-D, Broude EV, Fang J, et al. p21waf1/cip1/sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreplication in recovering cells. Oncogene. 2000;19:2165–2170
  15. Vitrat N, Chen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood. 1998;91:3711–3723
  16. Reiterer G, Yen A. Inhibition of the Janus Kinase family increases extracellular signal-regulated kinase ½ phosphorylation and causes endoreplication. Cancer Res. 2006;66:9083–9089
  17. Nakata S, Kawano T, Saito-Akita S, et al. MEK and p38MAPK inhibitors potentiate TNF-alpha induced apoptosis in U937 cells. Anticancer Res. 2001;21:167–171
  18. Yu C, Mao X, Li WX. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun. 2005;331:391–397
  19. Milella M, Precupanu CM, Gregorj C, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005;11:2779–2795
  20. Yu C, Krystal G, Varticovski R, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitor interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188–199
  21. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the duel Abl/Src inhibitor BMS-354-825. Blood. 2007;109:4006–4015
  22. Barancik M, Bohacova V, Sedlack J, Sulova Z, Breier A. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci. 2006;29:426–434
  23. Tazzari PL, Cappellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia. 2007;21:427–438
  24. Tabellini G, Cappellini A, Tazzari PL, et al. Phosphoinisitide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol. 2005;202:623–634
  25. Schwarzinger I, Valent P, Koller U, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol. 1990;8:423–430
  26. Repp R, Schaekel U, Helm G, et al. AML-SHG Study Group. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom. 2003;53:11–19
  27. Bradstock K, Matthews J, Benson E, Page F, Bishop J the Australian Leukemia Study Group. Prognostic value of immunophenotyping in acute myeloid leukemia. Blood. 1994;84:1220–1225
  28. Brouwer RE, Hoefnagel J, van der Burg B, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol. 2001;115:298–308
  29. Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84:287–297
  30. Baines P, Fisher J, Truran L, et al. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol. 2000;64:211–218
  31. Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloid leukemia. Leukemia. 1994;8:2065–2075
  32. Bradbury DA, Aldington S, Zhu Y-M, Russel NH. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Hematol. 1996;94:671–675
  33. Sato S, Tomoyasu S, Okabe-Kado J, et al. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol. 1996;24:37–42
  34. Amran D, Sancho P, Fernandez , et al. Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia via glutathione-independent reduction in intracellular drug accumulation. Biochim Biophys Acta. 2005;1743:269–279
  35. Ricciardi MR, McQueen T, Chism D, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19:1543–1549
  36. Morgan MA, Dolp O, Reuter CWM. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823–1834
  37. Bonati A, Lunghi P, Gammaitoni L, et al. MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. Hematol J. 2002;3:105–113
  38. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res. 2001;7:775–783
  39. Lunghi P, Tabilio A, Dall'Aglio PP, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003;17:1783–1793
  40. Wu J, Wong WW-L, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to Lovastin-induced apoptosis. Cancer Res. 2004;64:6461–6468
  41. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851–859

PII: S0301-472X(07)00536-X

doi: 10.1016/j.exphem.2007.08.027

Experimental Hematology
Volume 36, Issue 1 , Pages 28-36 , January 2008

Article Tools

* Image Usage & Resolution